Diagnóstico y tratamiento | 08 JUN 15

Enfermedad pulmonar intersticial

La enfermedad pulmonar intersticial es un grupo complejo de trastornos pulmonares, principalmente del intersticio pulmonar e incluye la fibrosis pulmonar idiopática, la neumonitis por hipersensibilidad, la sarcoidosis y la enfermedad del tejido conectivo asociada a la enfermedad pulmonar intersticial.
Autor/a: Adam Wallis, Katherine Spinks Fuente: BMJ 2015;350:h2072 The diagnosis and management of interstitial lung diseases.
INDICE:  1.  | 2. Referencias
Referencias

1 Navaratnam V, Fleming K, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011;66:462-7.
2 Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012;21:355-61.
3 Shah P, Hansell D, Lawson P, et al. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Thorax 2000;55:67-77.
4 Ley B, Collard H, King T, et al. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:431-40.
5 Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med 2011;184:842-7.
6 American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus
classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
7 Ryerson C, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Resp J 2013;42:750-7.
8 Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J 2008;31:372-9.
9 Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:1390-4.
10 García-Sancho C, Buendía-Roldán I, Fernández-Plata MR, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med 2011;105:1902-7.
11 Avouac J, Airo P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010;37:2290-8.
12 Wells AU, N Hirani N on behalf of the British Thoracic Society Interstitial Lung Disease Guideline Group. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63(Suppl V):v1-58.
13 Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009;136:10-5.
14 Mcleod T, Carrington C, Gaensler E. Diffuse interstitial lung disease: a new scheme for description. Radiology 1983;149:353-63.
15 Raghu G, Collard H, Egan J, et al. An Official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
16 Hansell D, Bankier A, MackMahon H, et al. Fleischner society: glossary of terms for thoracic imaging. Radiology 2008;246:697-722.
17 Jenkins RG, Simpson JK, Saini G, et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med 2015; published online 11 Mar.
18 National Institute for Health and Care Excellence. Idiopathic pulmonary fibrosis: the diagnosis and management of suspected idiopathic pulmonary fibrosis. (Clinical guideline 163.) 2013. http://guidance.nice.org.uk/cg163.
19 Hallstrand T, Boitano L, Johnson W, et al. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J 2005;25:96-103.
20 Travis W, Costabel U, Hansell D, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188;6:733-48.
21 Fell CD, Martinez FJ, Liu LX, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010;181:832-7.
22 Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012;185:1004-14.
23 Nguyen W, Meyer KC. Surgical lung biopsy for the diagnosis of interstitial lung disease: a review of the literature and recommendations for optimizing safety and efficacy. Sarcoidosis Vasc Diffuse Lung Dis 2013;30:3-16.
24 Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008;3:8-22. 25 Panther Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-77.
26 The Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2093-101.
 27 National Institute for Health and Care Excellence. Pirfenidone for treatment idiopathic pulmonary fibrosis. (Technology appraisal guidance 282.) 2013. www.nice.org.uk/guidance/ta282.
28 Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9.
29 King T, Bradford W, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92.
30 Richeldi L, du Bois R, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82.
31 Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
32 Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70.
33 Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885-9. 34 Israel HL, Sones M, Harrell D. Cortisone treatment of sarcoidosis-experience with thirty six cases. JAMA 1954;156:461-6.
35 Baughman R, Winget D, Lower E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:60.
36 Vorselaars A, Wuyts W, Vorselaars V, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest 2013;144:805.
37 Muller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999;14:1117-22.
38 Baltzan M, Mehta S, Kirkham TH, et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999;160:192-7.
39 Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795-802.
40 Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002;287:1301-7.
41 Thomeer M, Costabe U, Rizzato G, et al. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J Suppl 2001;32:114–8s.
42 Lota HK, Keir GJ, Hansell D, et al. Research letter: novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment. Thorax 2013;68:780-1.
43 Holland A, Hill C. Physical training for interstitial lung disease. Cochrane Database Syst Rev 2008;4:CD006322.
44 Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008;636:549-54.
45 Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008:13;394-9.
46 Yusen RD, Christie JD, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: thirtieth adult lung and heart-lung transplant report—2013;focus theme: age. J Heart Lung Transplant 2013;32:965-78.
47 Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006;25:745-55.
48 Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-min walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:1084-90.
49 Gottlieb J; European Respiratory Society. Rare indications for lung transplantation. In: Cordier JF, ed. European Respiratory Society monograph, 54th ed. European Respiratory Society; 2011;332-40.
50 Valapour M, Paulson K, Smith JM, et al. OPTN/SRTR 2011 Annual data report: lung. Am J Transplant 2013;13(Suppl 1):149-77.
51 Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 2009;136:1397-405.
52 King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis. Scoring system and survival model. Am J Respir Crit Care Med 2001;164:1171-81.
53 Nicholson A, Addis B, Bharucha H, et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax 2004;59:500-5.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023